Oramed Pharmaceuticals, Inc
ORMP
Get informed when a big investor buys or sells
+ FollowMarket Cap$171.8M
Close$
$0.98
76.2% downside
Current Fair Value
76.2% downsideOvervalued by 76.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $171.80 Million |
|---|---|
| Enterprise Value | $159.00 Million |
| Dividend Yield | $0.25 (6.05%) |
| Earnings per Share | $1.53 |
| Beta | 1.28 |
| Outstanding Shares | 41,040,479 |
Return
| Return on Equity | 58.63% |
|---|---|
| Return on Assets | 58.86% |
| Return on Invested Capital | 25.49% |
Valuation & Multiples
| P/E Ratio | 0.98 |
|---|---|
| PEG | 0.2 |
| Price to Sales | - |
| Price to Book Ratio | 0.69 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 2.04 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$0.15
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$0.43
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 25,000▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 41.07%▲ 8.60% |
|---|---|
| Total Invested | $81.07M▲ 80.09% |
| Investors Holding | 86▲ 22.00% |
ESG Score
No data
About Oramed Pharmaceuticals, Inc
13 employees
CEO: Nadav Kidron Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase I...